Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Effect of anti-IgE therapy in patients with peanut allergy.
- D. Leung, H. Sampson, +6 authors W. Shanahan
- The New England journal of medicine
- 13 March 2003
A 450-mg dose of TNX-901 significantly and substantially increased the threshold of sensitivity to peanut on oral food challenge from a level equal to approximately half a peanut to one equal to almost nine peanuts, an effect that should translate into protection against most unintended ingestions of peanuts. Expand
In vitro regulation of FcεRIα expression on human basophils by IgE antibody
Several characteristics suggest that the upregulation is mediated by IgE interacting through FcRIα itself, and this upregulation occurred in high-purity basophils, was not influenced by IgG at concentrations up to 1 mg/mL, and was inhibited by dimeric IgE. Expand
A new isoform of human membrane-bound IgE.
Rabbit antibodies, which were prepared by immunization using a peptide of 36 amino acid residues representing an encoded segment unique to mRNA species m/l, could specifically bind to human IgE-expressing B cell lines and react with an epsilon-chain on Western immunoblots indicate that there exists a previously unidentified isoform of human membrane-bound IgE. Expand
Efficacy, pharmacodynamics, and pharmacokinetics of CGP 51901, an anti‐immunoglobulin E chimeric monoclonal antibody, in patients with seasonal allergic rhinitis
- A. Racine‐Poon, L. Botta, +7 authors W. Frank
- Clinical pharmacology and therapeutics
- 1 December 1997
The efficacy, pharmacodynamics, and pharmacokinetics of CGP 51901, a recombinant monoclonal mouse—human chimeric anti‐human immunoglobulin E (IgE) antibody were evaluated for patients with seasonal allergic rhinitis and a sustained 85% or greater reduction of serum free IgE levels was shown to be effective in improving clinical symptoms. Expand
Humanized Anti-IgE mAb Hu-901 Prevents the Activation of Allergen-Specific T Cells
- R. V. van Neerven, C. V. van Roomen, W. Thomas, M. de Boer, E. Knol, F. Davis
- International Archives of Allergy and Immunology
- 1 March 2001
Data clearly indicate that anti-IgE antibodies for the treatment of allergy exert their effect not only by inhibiting mast cell/basophil degranulation, but also by preventing T cell activation, which possibly explains the effect of anti- IgE treatment on late-phase reactions noted in clinical studies. Expand
Transfectomas expressing both secreted and membrane-bound forms of chimeric IgE with anti-viral specificity.
The potential utility of the transfectoma cells and the chimeric IgE in studying the roles of membrane-bound IgE and effects of anti-IgE antibodies on IgE-producing B cells is demonstrated. Expand
The nucleolus, a model for analysis of chromatin controls.
Growth factor-mediated proliferation in B cell non-Hodgkin's lymphomas.
These studies suggest that human B cell lymphoid tumors are not only phenotypically similar to their normal B lymphocyte counterparts, but are also sensitive in some cases, to the same types of immunoregulatory molecules that control normal lymphoid cell growth. Expand
A nucleolar antigen found in a broad range of human malignant tumor specimens.
- H. Busch, F. Gyorkey, R. Busch, F. Davis, P. Gyorkey, K. Smetana
- Biology, Medicine
- Cancer research
- 1 August 1979
With rabbit antibodies to nuclear 0.01 M Tris-HCl, pH 8, extract or "nucleolar preparations" of human HeLa S3 cells and fluorescein-labeled goat anti-rabbit antibodies, bright nucleolar… Expand
The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics.
- J. Corne, R. Djukanović, +16 authors S. Holgate
- Chemistry, Medicine
- The Journal of clinical investigation
- 1 March 1997
The use of anti-human IgE antibody is safe and effective in reducing serum IgE levels in atopic individuals and provides a potential therapeutic approach to the treatment of atopic diseases. Expand